Dexamethasone pretreatment reduces GI complications in DLBCL patients with GI involvement without compromising efficacy. The study showed no significant differences in response rates or survival ...

For patients with B-cell lymphoma, the addition of Revlimid to standard R-CHOP did not improve progression-free survival nor event-free survival. The addition of Revlimid (lenalidomide) to standard ...

Although ibrutinib adds to the cost of treatment, its benefits over the long term justify the cost, investigators found. Adding ibrutinib (Imbruvica) to the R-CHOP regimen (rituximab, cyclophosphamide ...

Please provide your email address to receive an email when new articles are posted on . CHICAGO — Epcoritamab plus R-CHOP induced high complete metabolic response rates in previously untreated ...

Please provide your email address to receive an email when new articles are posted on . The regimen conferred a 71% complete response rate among older adults with newly diagnosed DLBCL. Median PFS and ...

R-CHOP plus ibrutinib followed by ibrutinib maintenance induced an ORR of 90% after 4 cycles and 85% at the end of induction. Adding ibrutinib to standard-of-care (SOC) R-CHOP resulted in a 77.7% ...

- Preliminary safety and efficacy data from Phase 1b firstMIND trial in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) presented today - Also presented today: Long-term subgroup ...

ATLANTA -- After 15 years as standard of care for previously untreated diffuse large B-cell lymphoma (DLBCL), R-CHOP has fallen to a new, though similar, regimen in a randomized trial. At a median ...

The combination of Epkinly and R-mini-CHOP showed a 93% ORR and 86% CR rate in elderly DLBCL patients. At two years, 79% of patients remained in complete response, with a 76% progression-free survival ...

Lenalidomide has significant single-agent activity in relapsed diffuse large B-cell lymphoma (DLBCL). We demonstrated that lenalidomide can be safely combined with R-CHOP (rituximab plus ...

Clinical Benefit and Safety of Reduced Elective Dose in Definitive Radiotherapy for Head and Neck Squamous Cell Carcinoma: The UPGRADE-RT Multicenter Randomized Controlled Trial The combination of ...